Buminate (human albumin) / Takeda - LARVOL DELTA

Tannic Acid and Ethacridine Lactate Attenuate Markers of Stress-Induced Intestinal Barrier Dysfunctions in Murine Small Intestinal Organoids. (PubMed, Biomolecules) - "(1) Background: Tannacomp® is a drug consisting of tannin albuminate, a complex of tannic acid (TA) and ethacridine lactate (Eta) used for treating acute and traveler's diarrhea...In addition, TA and Eta attenuated LPS- and GFRed-mediated gut barrier dysfunctions, with normalization of tight junction, adherent junction and mucin gene expression and reduction of Nod2- and matrix metalloproteinase 7-dependent activation of antimicrobial peptides. (4) our data show that TA and Eta modulate markers of inflammation and the intestinal barrier and suggest novel mechanisms of action of this drug that could broaden its treatment indications."

Biomarker • Journal • Preclinical • Gastroenterology • Gastrointestinal Disorder • Infectious Disease • Inflammation • Oncology • IL1B • IL6 • MMP7 • TNFA

SENECA: Stem Cell Injection in Cancer Survivors (clinicaltrials.gov) - P1; N=46; Completed; Sponsor: The University of Texas Health Science Center, Houston; Active, not recruiting ➔ Completed

Clinical • Trial completion • Cardiomyopathy • Cardiovascular • Oncology • MRI

SENECA: Stem Cell Injection in Cancer Survivors (clinicaltrials.gov) - P1; N=37; Active, not recruiting; Sponsor: The University of Texas Health Science Center, Houston; Trial completion date: Aug 2020 ➔ May 2020

Trial completion date • MRI

Factor Xa Inhibitor Antidote, Andexanet Alfa Differentially Reverses the Effects of Apixaban, Betrixaban, Edoxaban and Rivaroxaban (ISTH 2019) - "Apixaban, betrixaban, edoxaban and rivaroxaban were diluted in pH 8.4, 0.5 M tris buffer (TB), blood bank plasma (BBP) and in 5% albuminated buffer (AB) at 0.062 - 1.0 ug/ml. Each of the four anti-Xa agents exhibit varying degrees of matrix independent anti-Xa potencies in different systems, the collective order follows edoxaban > apixaban > betrixaban > rivaroxaban. Andexanet alfa produced matrix dependent differential neutralization of the anti-Xa effects of these agents. Andexanet alfa is most effective in neutralizing betrixaban and requires relatively higher concentrations to neutralize edoxaban."

SENECA: Stem Cell Injection in Cancer Survivors (clinicaltrials.gov) - P1; N=37; Active, not recruiting; Sponsor: The University of Texas Health Science Center, Houston; Trial completion date: Nov 2019 ➔ Aug 2020

Clinical • Trial completion date